Novo Nordisk Trots Along Waiting for Its Next-Generation Oral Drug

Novo Nordisk (NYSE: NVO) continued its slow-but-steady growth as it waits for an inflection point from the launch of oral semaglutide, which should be approved by the FDA later this year.